On The Path To Regeneration: NovaGo’s New Approach To Stroke

Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.

Tree — NovaGo is hoping to prove CNS regeneration is possible and efficacious • Source: Shutterstock

Swiss start up, NovaGo Therapeutics, co-founded by Zurich University professor Martin Schwab and Neurimmune Holdings AG founder and president Roger Nitsch, is based on Schwab’s discovery of inhibitors of neurite growth which cause the absent regeneration of injured fiber tracts in the central nervous system.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

On The Path To Regeneration: NovaGo’s New Approach To Stroke

Read the full article – start your free trial today!

More from Cell Therapies

More from Advanced Therapies